At AgenTus Therapeutics, our platform is composed of scalable allogeneic iNKT cell production, novel cancer target identification capabilities, CAR and TCR engineering for precision targeting, and a collaboration with Agenus for access to checkpoint antibody combination therapies.

Our platform is capable of rapidly generating a pipeline of first-in-class, off-the-shelf treatments for hematologic and solid cancers as well as infectious disease.

iNKT cells can be modified with CARs and TCRs, or redirected by bispecific engagers, to target specific cancer cells and to further enhance tumor killing. We are exploiting our extensive antibody knowledge and proprietary mammalian display screening platforms for identification of CAR candidates optimally tuned to further enhance the native iNKT capabilities for tackling solid tumors, an area not well served by existing cell therapies.